Why Prescription Drug Prices Are So High in the United States

Every year, millions of Americans face a brutal choice: pay for their medicine or pay for rent, groceries, or electricity. It’s not a hypothetical dilemma - it’s daily reality for people with diabetes, cancer, or rare diseases. The same pill that costs $30 in Canada or €25 in Germany can cost over $500 in the U.S. Why? The answer isn’t one thing. It’s a system built over decades that rewards profit over people.

The System Is Designed This Way

The U.S. doesn’t have high drug prices because of bad luck or corporate greed alone. It’s because the rules were written to allow it. In 2003, Congress passed the Medicare Modernization Act. One clause stood out: Medicare was banned from negotiating drug prices with manufacturers. That’s not how it works anywhere else in the developed world. Countries like the UK, Germany, and Canada negotiate directly. They say, “We’ll buy this drug, but not at your list price.” The U.S. said nothing. That single decision gave drug companies a blank check.

Fast forward to 2025, and the results are clear. Americans pay over three times more for brand-name drugs than people in other OECD countries. The same medication - Galzin for Wilson’s disease - costs $88,800 a year here. In the UK, it’s $1,400. That’s not a pricing error. That’s a policy choice.

Who’s Really in Charge? Meet the Middlemen

You might think drug prices are set by manufacturers alone. But there’s a hidden layer: Pharmacy Benefit Managers, or PBMs. These are the middlemen between drug makers, insurers, and pharmacies. Originally, they were supposed to cut costs by negotiating discounts. Today, they’re big corporations that own pharmacies, insurance plans, and even drug manufacturers. Their profit? It comes from rebates - and the higher the list price, the bigger the rebate.

Here’s how it works: A drug company sets a list price of $1,000. The PBM negotiates a $300 rebate. The final price to the insurer is $700. But the list price stays at $1,000. That’s the number you see on your pharmacy receipt. The patient pays based on that inflated price - even if their insurance only covers part of it. So PBMs have a financial incentive to keep prices high. It’s a perverse system where the people meant to lower costs actually profit from them.

Specialty Drugs Are Breaking the Bank

Not all drugs are created equal. The biggest price spikes come from specialty drugs - treatments for cancer, rare diseases, obesity, and diabetes. These aren’t generic pills. They’re complex biologics, often made with cutting-edge science. But that doesn’t justify what’s happening.

Take Ozempic and Wegovy. These drugs for diabetes and weight loss cost over $1,000 a month in the U.S. In 2025, the White House announced deals with manufacturers to cut those prices to $350. That’s progress. But here’s the catch: those deals only apply to Medicare. Millions of people with private insurance still pay full price. And even $350 a month is $4,200 a year - more than most people spend on rent.

IQVIA reports that novel obesity and diabetes drugs drove an 11.4% increase in U.S. drug spending in 2024. That’s not just inflation. That’s a business model built on locking patients into lifelong, high-cost therapies.

The Inflation Reduction Act - A Start, But Not a Solution

In 2022, Congress passed the Inflation Reduction Act. For the first time, Medicare could negotiate prices for a small number of drugs. In 2026, that list includes ten drugs - all high-cost, high-demand medications. The projected savings? $1.5 billion in out-of-pocket costs for seniors.

That sounds good. But look closer. There are 10,000+ prescription drugs on the market. Ten is less than 0.1%. And even that limited power was weakened in 2025 by a budget reconciliation bill that reduced funding for the negotiation program. Meanwhile, drug companies are still allowed to raise prices faster than inflation - unless they’re on the negotiation list. For the rest? No limits.

The law also created a $2,000 annual cap on out-of-pocket drug costs for Medicare beneficiaries. That’s huge. For someone taking three expensive medications, that could mean saving $5,000 a year. But it only helps seniors on Medicare. It doesn’t touch the 150 million Americans with private insurance.

Why Other Countries Don’t Have This Problem

Germany uses reference pricing. If a new drug costs more than similar ones already on the market, the government says, “We won’t pay more than the average.” France negotiates directly with manufacturers before a drug even hits shelves. Canada uses bulk purchasing and price caps. None of them let companies set prices at will.

The U.S. is the only OECD country without any form of direct price control. And it’s not because we’re smarter or more innovative. It’s because we have a powerful pharmaceutical lobby that spends over $300 million a year on lobbying and campaign donations. The system works perfectly - for them.

What’s Really at Stake?

The human cost is staggering. One in four Americans says they’ve skipped a dose, cut a pill in half, or gone without medication because they couldn’t afford it. A 2025 report from the Center for American Progress found that Project 2025’s proposed drug plan would increase costs for 18.5 million seniors and people with disabilities. That’s not policy debate. That’s lives.

Senator Bernie Sanders’ 2025 report found that 688 prescription drugs increased in price since President Trump took office - despite his public promises to lower costs. The White House claims progress with recent deals on Ozempic and Wegovy. But those deals don’t apply to most people. And in the same month, 87 other drugs saw price hikes averaging 8%.

This isn’t about whether a drug is “worth” its price. It’s about whether a society that lets people die because they can’t afford medicine can call itself healthy.

What’s Next?

The path forward isn’t simple. But it’s clear: we need real price controls, not just negotiations on a handful of drugs. We need to ban rebate-based pricing that rewards high list prices. We need to let Medicare negotiate for all drugs, not ten. And we need transparency - real-time pricing data so patients know what they’re paying before they fill the prescription.

The system isn’t broken. It’s working exactly as designed. And until we change the design, prices will keep climbing - and people will keep choosing between medicine and meals.